Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Acasti Pharma Inc announces pricing of $20 million offering of units

Wednesday, 27 Nov 2013 09:19am EST 

Acasti Pharma Inc:Says it has priced an underwritten public offering of 16,000,000 units of Acasti at a price of $1.25 per Unit.Says each Unit consisting of one Class A share (Common Share) and one Common Share purchase warrant (Warrant) of the company.Says each Warrant will entitle the holder to purchase one Common Share at an exercise price of $1.50 per Warrant Share.Says gross proceeds to Acasti, before underwriting commissions and other offering expenses, are expected to be about $20 million.Says intends to allocate the net proceeds to complete its current Phase II double blind clinical trial and for general corporate and other working capital purposes. 

Company Quote

0.0032 +1.01%
12:38pm EDT